FREMONT, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announced today that the Nasdaq Listing Qualifications Panel has informed the Company that it has evidenced compliance with the requirements for continued listing on The Nasdaq National Market and that the “E” that has been appended to the Company’s ticker symbol will be removed effective at the open of business on Wednesday, January 25, 2006.
About Ciphergen
Ciphergen is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at www.ciphergen.com.
NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc.
Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers, Investor Relations, of Ciphergen Biosystems,Inc., +1-510-505-2233
Web site: http://www.ciphergen.com//